Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Rating) has been given a consensus rating of “Hold” by the nine ratings firms that are covering the firm, reports Marketbeat.com. One equity research analyst has rated the stock with a sell recommendation, four
More than 1 million tickets sold for 2023 Women’s World Cup
The tournament is on track to become the most attended standalone women’s sporting event in history as the field expands to 32 teams for the first time.
SYDNEY, NSW — More than 1 million tickets have been sold for the
